7:09 PM
 | 
Jul 27, 2007
 |  BC Extra  |  Company News

OSI selling anti-PDGF program

OSIP granted Ophthotech (Newton Centre, Mass.) rights to its anti-PDGF aptamer program, including E10030, a preclinical compound for wet age-related macular degeneration (AMD). OSIP will receive an undisclosed...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >